glp-1 pharmacokinetics and the kidney: from physiology to pharmacology and outcomes in diabetes Discovery of Small-Molecule GLP-1 Receptor

This undermines the reset in multiple ways

Most clinical trials reporting weight loss outcomes involved people taking 2.4 mg of semaglutide, the maximum dose of Wegovy (a version of semaglutide thats specifically indicated for weight loss)

*Not everyone naturally has the Akkermansia muciniphila strain in their gut microbiome, our GLP-1 supports growth in those who naturally have the strain

If you experience any suspected side effects, you can report them through the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk)

Clinicians may accelerate titration due to patient demand for faster weight loss or improved glucose control